Skip to main content
NIH funding notice PAR-21-334

Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)

Closed on June 11, 2024.

Posted
September 16, 2021
Close date
June 11, 2024
Activity codes
U01
Institutes taking part
NCI

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page names no earlier notice: it is new, or it does not say.

Replaced by PAR-28-056.

Who won it before

10 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $8,409,368 in first-year total cost, median $818,975.

Most frequent study sections

  1. Special Emphasis Panel[ZCA1 RPRB-8 (M2)]6
  2. Special Emphasis Panel[ZCA1 RPRB-T (J2)]2
  3. Special Emphasis Panel[ZCA1 SRB-K (J1)]2

Most frequent institutions

  1. JOHNS HOPKINS UNIVERSITY2
  2. BECKMAN RESEARCH INSTITUTE/CITY OF HOPE1
  3. DANA-FARBER CANCER INST1
  4. MAYO CLINIC ROCHESTER1
  5. NEW YORK UNIVERSITY SCHOOL OF MEDICINE1
Competing awards under PAR-21-334 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Using microvolumetric cyst fluid proteolysis for early detection of pancreatic cancer1U01CA282269-01A1KIRKWOOD, KIMBERLY SAUNDERSUNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA$812,450ZCA1
2024Circulating Biomarkers and Imaging for Early Detection of Pancreatic Cancer2U01CA214263-06KILLARY, ANN MKOAY, EUGENE JSEN, SUBRATAUNIVERSITY OF TX MD ANDERSON CAN CTR, TX$799,728ZCA1
2023Exosome-based microRNA biomarkers for Non-invasive and Early Detection of Pancreatic Cancer2U01CA214254-06GOEL, AJAYVON HOFF, DANIEL DBECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA$923,881ZCA1
2023Biomarker Validation in Pancreatic Cystic Neoplasms1U01CA282272-01SIMEONE, DIANE MTSIRIGOS, ARISTOTELISNEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY$898,256ZCA1
2023Development of a panel of multiplex biomarkers for the early detection of pancreatic ductal adenocarcinoma and high-risk lesions1U01CA274514-01A1BRAND, RANDALLCHAN, DANIEL WANYUIZHANG, HUIZHANG, ZHENJOHNS HOPKINS UNIVERSITY, MD$825,499ZCA1
2023Validation of novel imaging and molecular tests for early detection of pancreatic cancer through risk-stratified community engagement programs1U01CA278923-01COTE, GREGORY AGUIMARAES, ALEXANDER SAVIO RAMOSSEARS, ROSALIE CSHEPPARD, BRETT COREGON HEALTH & SCIENCE UNIVERSITY, OR$766,920ZCA1
2022Altered metabolism and machine learning for pancreatic cancer early detection2U01CA210171-06ROSENTHAL, MICHAEL H.WOLPIN, BRIAN MATTHEWDANA-FARBER CANCER INST, MA$925,639ZCA1
2022Pancreatic Cancer Detection Consortium2U01CA210240-06HOLLINGSWORTH, MICHAEL A.UNIVERSITY OF NEBRASKA MEDICAL CENTER, NE$857,987ZCA1
2022Mayo Clinic Prospective Resource for Biomarker Validation and Early Detection of Pancreatic Cancer2U01CA210138-06MAJUMDER, SHOUNAKZARET, KENNETHMAYO CLINIC ROCHESTER, MN$812,380ZCA1
2022Using markers to improve pancreatic cancer screening and surveillance: a multi-center study2U01CA210170-06GOGGINS, MICHAEL G.JOHNS HOPKINS UNIVERSITY, MD$786,628ZCA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-21-334: Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional) | ScienceDex | ConductScience